Torrent Pharma Q2 net profit dips 12 percent to Rs 179 crore
New Delhi: Drug firm Torrent Pharmaceuticals has reported a 12.25 per cent dip in its consolidated net profit to Rs 179 crore for the quarter ended September 2018 due to the one-time impact of a product recall in the US and rupee depreciation. The company had posted a net profit of Rs 204 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a statement.
Its total revenue, however, on a consolidated basis rose to Rs 1,894 crore for the quarter under consideration as against Rs 1,417 crore for the same period a year ago.
The company's net profit was impacted as depreciation and amortisation was higher by Rs 68 crore on account of acquired business, the one-time impact of a product recall in US of Rs 25 crore and lower hedging gains due to rupee depreciation, Torrent Pharmaceuticals said.
The research and development spend for the second quarter this fiscal was also higher at Rs 136 crore as against Rs 107 crore in the year-ago period, it added
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd